VIA ELECTRONIC MAIL

Elinore F. McCance-Katz, M.D., Ph.D.
Assistant Secretary for Mental Health and Substance Use
Substance Abuse and Mental Health Services Administration
5600 Fishers Lane, Rockville, MD 20857

Re: Confidentiality of Substance Use Disorder Patient Records (SAMHSA-4162-20)

Dear Assistant Secretary McCance-Katz:

The Health Care Transformation Task Force (HCTTF or Task Force) appreciates the opportunity to comment on the Substance Abuse and Mental Health Services Administration (SAMHSA) proposed rule on the Confidentiality of Substance Use Disorder (SUD) Patient Records (Proposed Rule), which proposes changes to 42 CFR Part 2.

The HCTTF is a leading private sector, multi-stakeholder consortium that supports accelerating the pace of transforming the delivery system into one that better pays for value. Representing a diverse set of organizations from various segments of the industry – including providers, health plans, employers, and consumers – we share a common commitment to transform our respective businesses and clinical models to deliver better health and better care at reduced costs. Integration of behavioral health services and comprehensive care coordination is critical to delivering high-quality, patient-centered care for patients with substance use disorders.

We appreciate that SAMHSA recognizes the significant confusion and misunderstanding surrounding the applicability of Part 2 rules. The Task Force does not take a position on the proposed modifications to Part 2; our diverse membership was not able to reach consensus on this issue. However, Task Force members are concerned that the proposal misses an opportunity to address significant areas of ambiguity regarding the applicability of Part 2. The Proposed Rule does not, for instance, further clarify what "holds itself out" means in the Part 2 program definition. The ambiguity creates undue burden and confusion for patients and non-Part 2 health care stakeholders that provide treatment and/or health care operations services for patients with SUD. In this letter, the Task Force identifies two opportunities for SAMHSA to further mitigate confusion and encourage better care coordination and high-quality care for SUD patients.
I. Identifying a Part 2 Provider

In the Proposed Rule, SAMHSA offers clarification for the purpose of encouraging care coordination among providers, including clarification of what constitutes a Part 2 record and its applicability to ensure that non-Part 2 providers are not discouraged from caring for SUD patients. Yet, our members report that one of the greatest challenges to complying with the Part 2 rule is the lack of clarity about what providers are covered by Part 2 for all other stakeholders that interact with probable Part 2 programs. Since the determination of Part 2 applicability falls to the Part 2 provider, non-Part 2 providers and other lawful holders – including health insurers – are subject to compliance without knowing with any certainty when they are interacting with providers and patient records covered by Part 2.

This lack of clarity about what providers and records are subject to Part 2 presents a barrier to patients as well. While the definition of a Part 2 program includes individuals and entities that “hold itself out” as providing SUD diagnosis, treatment, or referral for treatment, there exists no requirement for Part 2 providers to identify themselves publicly as a Part 2 covered provider to patients and other stakeholders. Considering the intent of the Part 2 rules to encourage individuals to seek treatment for substance use disorders by imposing stricter requirements about disclosure of substance use-related information, it stands to reason that SUD patients would benefit from the ability to make informed choices about their selection of care provider, including whether that provider is subject to the Part 2 rules.

The Task Force strongly recommends that SAMHSA engage with impacted stakeholders and issue a report on potential mechanisms to reduce ambiguity in Part 2 program identification. The assessment should include an analysis of the excess compliance burden due to the lack of public identification of Part 2 programs and what information would be helpful for patients to make choices about SUD treatment providers.

II. Audit and evaluation

In its 2018 rule, SAMHSA finalized changes to specify that Part 2 disclosures are allowable to contractors, subcontractors, or legal representatives under §2.53 to carry out a Medicare, Medicaid, or CHIP audit or evaluation. In the preamble to the final rule (83 FR 246), SAMHSA uses the example of accountable care organizations (ACOs) and similar CMS-regulated health models as entities that may need to access all of the records, including Part 2 program records, in order to evaluate the impact of integrated care programs. HHS should clarify how CMS will implement this authority in coordination with SAMHSA, and how those providers that meet the stated criteria may access the claims data for the purpose of audits and evaluation. For example, CMS could provide model data-use agreements or a memorandum of understanding and clarify the process for eligible participants to make a request for this data from CMS for evaluation and audit purposes.
III. Education and Technical Assistance

Many stakeholders including the Medicaid and CHIP Payment and Access Commission have asked HHS to conduct a coordinated effort to provide education and technical assistance to providers, patients, and other entities around Part 2. Jessie’s Law of 2018\(^1\) provided that the Secretary of Health and Human Services, in consultation with appropriate experts, should identify and/or develop and disseminate model programs and materials for training a range of stakeholders concerning the permitted uses and disclosures of SUD records pursuant to Part 2, including training for patients and their families regarding their rights to protect and obtain information under the Part 2 standards and regulations. **The Task Force supports this requirement and encourages the Department to comply with producing and disseminating training materials in a timely manner.** These materials were to be disseminated no later than one year after the enactment of Jessie’s Law in October 2018.

*****

The Task Force appreciates the opportunity to advise SAMHSA on this matter. Please contact HCTTF Senior Director Clare Pierce-Wrobel (clare.wrobel@hcttf.org or 202-774-1565) with any questions or to follow up to this letter.

Regards,

**Angela Meoli**  
Executive Vice President and President of Government Services  
Aetna, A CVS Health Company

**Hoangmai Pham, MD**  
Vice President, Provider Alignment Solutions  
Anthem, Inc.

**Stuart Levine, MD**  
Chief Medical and Innovation Officer  
agilon health

**Jordan Hall**  
Executive Vice President, Accountable Care Operations  
ApolloMed

**Sean Cavanaugh**  
Chief Administrative Officer  
Aledade, Inc.

**David Terry**  
Founder & Chief Executive Officer  
Archway Health

**Shawn Martin**  
Senior Vice President, Advocacy, Practice Advancement and Policy  
American Academy of Family Physicians

**Peter Leibold**  
Chief Advocacy Officer  
Ascension

---

Marci Sindell  
Chief Marketing Officer and SVP, External Affairs  
Atrius Health

Jamie Colbert, MD  
Senior Medical Director, Delivery System Innovation and Analytics  
Blue Cross Blue Shield of Massachusetts

Todd Van Tol  
Senior Vice President, Health Care Value  
Blue Cross Blue Shield of Michigan

Rahul Rajkumar, MD  
Senior Vice President and Chief Medical Officer  
Blue Cross Blue Shield of North Carolina

Ann T. Burnett  
Vice President  
Provider Network Innovations & Partnerships  
Blue Cross Blue Shield of South Carolina

Catherine Gaffigan, MD  
Vice President, Network Management & Provider Partnership Innovation  
Cambia Health

Gaurov Dayal, MD  
Executive Vice President, Chief of Strategy & Growth  
ChenMed

Jean Drouin, MD  
Founder and Chief Executive Officer  
Clarify Health

Adam Myers, MD  
Chief of Population Health and Chair of Cleveland Clinic Community Care  
Cleveland Clinic

Susan Sherry  
Deputy Director  
Community Catalyst

Shelly Schlenker  
Vice President of Public Policy, Advocacy & Government Relations  
Dignity Health

Mark McClellan, MD, PhD  
Director  
Duke Margolis Center for Health Policy

David Klementz  
Chief Strategy and Development Officer  
Encompass Health

Chris Dawe  
Senior Vice President  
Evolent Health

Frederick Isasi  
Executive Director  
Families USA

Sarah Samis  
Vice President, Care Delivery and Payment Transformation  
Geisinger

Richard Lipeles  
Chief Operating Officer  
Heritage Provider Network

Jim Sinkoff  
Deputy Executive Officer and Chief Financial Officer  
HRH Care Community Health

Anthony Barrueta  
Senior Vice President, Government Relations  
Kaiser Permanente
Leonardo Cuello
Director
National Health Law Program

Erin Mackay
Associate Director, Health Information Technology
National Partnership for Women & Families

Bill Kramer
Executive Director for National Health Policy
Pacific Business Group on Health

Michael Esters
Chief Population Health Officer
Partners HealthCare

Blair Childs
Senior Vice President, Public Affairs
Premier

Faith Cristol
Senior Vice President, Government Affairs
Remedy

Jordan Asher, MD
Senior Vice President and Chief Physician Executive
Sentara Healthcare

Emily Brower
SVP Clinical Integration & Physician Services
Trinity Health

Mary Beth Kuderik
Chief Strategy & Financial Officer
UAW Retiree Medical Benefits Trust

J.D Fischer
Program Specialist
Washington State Heath Care Authority